Global Long Acting Contraception Market Overview:
Global Long Acting Contraception Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Long Acting Contraception Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Long Acting Contraception involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Long Acting Contraception Market:
The Long Acting Contraception Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Long Acting Contraception Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Long Acting Contraception Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Long Acting Contraception market has been segmented into:
Implants
Intrauterine Devices
Injectables
Pills
By Application, Long Acting Contraception market has been segmented into:
Subdermal
Intrauterine
Intramuscular
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Long Acting Contraception market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Long Acting Contraception market.
Top Key Players Covered in Long Acting Contraception market are:
Bioniche Pharma
DKT International
Merck
Ferring Pharmaceuticals
Shionogi
Bayer
Teva Pharmaceutical Industries
BristolMyers Squibb
Mylan
Sage Therapeutics
Johnson and Johnson
Pfizer
Amgen
HRA Pharma
Cernea
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Long Acting Contraception Market Type
4.1 Long Acting Contraception Market Snapshot and Growth Engine
4.2 Long Acting Contraception Market Overview
4.3 Implants
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Implants: Geographic Segmentation Analysis
4.4 Intrauterine Devices
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Intrauterine Devices: Geographic Segmentation Analysis
4.5 Injectables
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Injectables: Geographic Segmentation Analysis
4.6 Pills
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Pills: Geographic Segmentation Analysis
Chapter 5: Long Acting Contraception Market Application
5.1 Long Acting Contraception Market Snapshot and Growth Engine
5.2 Long Acting Contraception Market Overview
5.3 Subdermal
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Subdermal: Geographic Segmentation Analysis
5.4 Intrauterine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Intrauterine: Geographic Segmentation Analysis
5.5 Intramuscular
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Intramuscular: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Long Acting Contraception Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BIONICHE PHARMA
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 DKT INTERNATIONAL
6.4 MERCK
6.5 FERRING PHARMACEUTICALS
6.6 SHIONOGI
6.7 BAYER
6.8 TEVA PHARMACEUTICAL INDUSTRIES
6.9 BRISTOLMYERS SQUIBB
6.10 MYLAN
6.11 SAGE THERAPEUTICS
6.12 JOHNSON AND JOHNSON
6.13 PFIZER
6.14 AMGEN
6.15 HRA PHARMA
6.16 CERNEA
Chapter 7: Global Long Acting Contraception Market By Region
7.1 Overview
7.2. North America Long Acting Contraception Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Implants
7.2.2.2 Intrauterine Devices
7.2.2.3 Injectables
7.2.2.4 Pills
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Subdermal
7.2.3.2 Intrauterine
7.2.3.3 Intramuscular
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Long Acting Contraception Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Implants
7.3.2.2 Intrauterine Devices
7.3.2.3 Injectables
7.3.2.4 Pills
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Subdermal
7.3.3.2 Intrauterine
7.3.3.3 Intramuscular
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Long Acting Contraception Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Implants
7.4.2.2 Intrauterine Devices
7.4.2.3 Injectables
7.4.2.4 Pills
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Subdermal
7.4.3.2 Intrauterine
7.4.3.3 Intramuscular
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Long Acting Contraception Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Implants
7.5.2.2 Intrauterine Devices
7.5.2.3 Injectables
7.5.2.4 Pills
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Subdermal
7.5.3.2 Intrauterine
7.5.3.3 Intramuscular
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Long Acting Contraception Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Implants
7.6.2.2 Intrauterine Devices
7.6.2.3 Injectables
7.6.2.4 Pills
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Subdermal
7.6.3.2 Intrauterine
7.6.3.3 Intramuscular
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Long Acting Contraception Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Implants
7.7.2.2 Intrauterine Devices
7.7.2.3 Injectables
7.7.2.4 Pills
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Subdermal
7.7.3.2 Intrauterine
7.7.3.3 Intramuscular
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Long Acting Contraception Scope:
|
Report Data
|
Long Acting Contraception Market
|
|
Long Acting Contraception Market Size in 2025
|
USD XX million
|
|
Long Acting Contraception CAGR 2025 - 2032
|
XX%
|
|
Long Acting Contraception Base Year
|
2024
|
|
Long Acting Contraception Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Bioniche Pharma, DKT International, Merck, Ferring Pharmaceuticals, Shionogi, Bayer, Teva Pharmaceutical Industries, BristolMyers Squibb, Mylan, Sage Therapeutics, Johnson and Johnson, Pfizer, Amgen, HRA Pharma, Cernea.
|
|
Key Segments
|
By Type
Implants
Intrauterine Devices
Injectables
Pills
By Applications
Subdermal
Intrauterine
Intramuscular
|
